Plant-based vaccines for Alzheimer's disease: An overview

Expert Review of Vaccines

Volumn 13, Issue 3, 2014, Pages 429-441

  Rosales Mendoza, Sergio ^a   Rubio Infante, Néstor ^b   Zarazúa, Sergio ^a   Govea Alonso, Dania O ^a   Martel Gallegos, Guadalupe ^a   Moreno Fierros, Leticia ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

secretase

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; IMMUNOTHERAPY; LYCOPERSICON ESCULENTUM; MICE; ORYZA SATIVA; PHYTOTHERAPY; PLANT VIRUSES; SOLANUM TUBEROSUM; TAU PROTEINS; TAUOPATHIES; TOBACCO; VACCINATION;

EID: 84894080322     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.874948     Document Type: Review

References (85)

1. McKhann G, Drachman D, Folstein et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-44
2. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003;74:1206-9
3. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-60
4. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7
5. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368: 387-403
6. Furukawa K, Sopher BL, Rydel RE, et al. Increasedactivity-regulating and neuroprotectiveefficacy of alpha-secretasederived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996;67:1882-96
7. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997;77:1081-132
8. Urbanc B, Betnel M, Cruz L, et al. Structural basis for Ab1-42 toxicity inhibition by Ab C-terminal fragments: discrete molecular dynamics study. J Mol Biol 2011;410(2):316-28
9. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-41
10. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765-7
11. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrinmetalloprotease. Proc Natl Acad Sci U S A 1999;96: 3922-7
12. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-5
13. Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 2005;280:30797-806
14. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44: 181-93 . Describes the effects caused by the Ab aggregates in Alzheimer's disease.
15. Avila J, Lucas JJ, Perez M, et al. Role of Tau protein in both physiological and pathological conditions. Physiol Rev 2004;84:361-84 . Provides a wide view of the Tau role in Alzheimer disease.
16. von Bernhardi R, Alarco'n R, Mezzano D, et al. Blood cells cholinesterase activity in early stage Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2005;19:204-12
17. Schaffer BA, Bertram L, Miller BL, et al. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol 2008;65:1368-74
18. Amenta F, Parnetti L, Gallai V, et al. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev 2001;122:2025-40
19. Giacobini E. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging (Milano) 2001;13:247-54
20. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
21. In t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21
22. Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 2001;366:2815-22
23. Bachmann MF, Whitehead P. Active immunotherapy for chronic diseases. Vaccine 2013;31:1777-84
24. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
25. Delrieu J, Ousset PJ, Caillaud C, et al. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 2012;120(Suppl 1):186-93
26. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002;40:260-9
27. Panza F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimer's disease: from anti-b-amyloid to Tau-based immunization strategies. Immunotherapy 2012;4:213-38
28. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
29. Kofler J, Lopresti B, Janssen C, et al. Preventive immunization of aged and juvenile non-human primates to b-amyloid. J Neuroinflammation 2012;3:84
30. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002;420:879-84
31. Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013;15: 319-26
32. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15:447-50
33. Wisniewski T, Boutajangout A. Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med 2010;77:17-31
34. Sigurdsson EM. Immunotherapy targeting pathological Tau protein in Alzheimer's disease and related Tauopathies. J Alzheimers Dis 2008;15:157-68
35. Romo-Gonza'lez T, Chavarri'a A, Pe'rez-H J. Central nervous system: a modified immune surveillance circuit? Brain Behav Immun 2012;26:823-9
36. Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24:1733-44
37. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101: 466-8
38. Deane R, Sagare A, Hamm K, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005;25:11495-503
39. Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 2001;57:957-64
40. Carson MJ, Thrash JC, Walter B. The cellular response in neuroinflammation: the role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin Neurosci Res 2006;6:237-45
41. Ransohoff RM. Snip-snip, kill-kill: truncated SDF-1 and HIV-associated neurodegeneration. Nat Neurosci 2003;6: 1009-11
42. Prat A, Biernacki K, Wosik K, et al. Glial cell influence on the human blood-brain barrier. Glia 2001;36:145-55
43. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010;120: 1368-79
44. Bechmann I. Failed central nervous system regeneration: a downside of immune privilege? Neuromolecular Med 2005;7: 217-28
45. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-19 . Reports one important approach in the progression of the Alzheimer disease in a murine model.
46. Wang A, Das P, Switzer RC III, et al. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-b immunotherapy. J Neurosci 2011;31:4124-36 . Describes the role of the Ab immunotherapy in the Alzheimer's disease in a murine model.
47. Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets 2010;9:207-16
48. Asuni AA, Boutajangout A, Quartermain D. Immunotherapy targeting pathological Tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-29 . Analyzes the elicitation of the immune response in the brain by immunization in mucosal surfaces.
49. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 2009;8: 128-43
50. Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal Tau protein. Arch Neurol 2006;63:1459-67
51. Boimel M, Grigoriadis N, Lourbopoulos A, et al. Efficacy and safety of immunization with phosphorylated Tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-85
52. Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012;1:50-63
53. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 2004;4: 407-19
54. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331-41
55. Field M. Modes of action of enterotoxins from Vibrio cholerae and Escherichia coli. Rev Infect Dis 1979;1:918-26
56. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral mucosal adjuvant and antigen vector systems. Vaccine 1993;11:1179-84
57. Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S. Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep 2011;30:1367-82
58. Kim HS, Youm JW, Moon KB, et al. Expression analysis of human b-secretase in transgenic tomato fruits. Protein Expr Purif 2012;82:125-31
59. Youm JW, Jeon JH, Kim H, et al. High-level expression of a human b-site APP cleaving enzyme in transgenic tobacco chloroplasts and its immunogenicity in mice. Transgenic Res 2010;19:1099-108
60. Szabó B, Hori K, Nakajima A, et al. Expression of amyloid-beta 1-40 and 1-42 peptides in Capsicum annum var. angulosum for oral immunization. Assay Drug Dev Technol 2004;2:383-8
61. Vitti A, Piazzolla G, Condelli V, et al. Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease. J Virol Methods 2010;169:332-40
62. Ishii-Katsuno R, Nakajima A, Katsuno T, et al. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination. Biochem Biophys Res Commun 2010;399:593-9
63. Hori K, Watanabe Y. Construction of tobamovirus vector that can systematically spread and express foreign gene products in Solanaceous plants. Plant Biotechnol 2003;20:129-36
64. Kim HS, Euym JW, Kim MS, et al. Expression of human amyloid-b peptide in transgenic potato. Plant Sci 2003;165: 1445-51
65. Youm JW, Kim H, Han JH, et al. Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. FEBS Lett 2005;579:6737-44 . Reports a proof of the concept for a plant-based Alzheimer's vaccine.
66. Youm JW, Jeon JH, Kim H, et al. Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease. Biotechnol Lett 2008;30:1839-45
67. Yoshida T, Kimura E, Koike S, et al. Transgenic rice expressing amyloid b-peptide for oral immunization. Int J Biol Sci 2011;7:301-7 . Constitutes one of the most well-characterized plant-based Alzheimer's vaccine candidate.
68. Nojima J, Ishii-Katsuno R, Futai E, et al. Production of anti-amyloid b antibodies in mice fed rice expressing amyloid b. Biosci Biotechnol Biochem 2011;75:396-400 . Presents one of the most well-characterized Alzheimer's-based immunization model that includes immunoprotection assessment.
69. Nojima J, Maeda A, Aoki S, et al. Effect of rice-expressed amyloid b in the Tg2576 Alzheimer's disease transgenic mouse model. Vaccine 2011;29:6252-8 . Describes a new molecular approach that allows for a substantial improvenment in the induction of antibodies able to reduce Ab levels.
70. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related Tauopathies. Curr Alzheimer Res 2009;6:446-50
71. Go'mez-Ramos A, Diaz-Hernandez M, Rubio A, et al. Extracellular Tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 2008;37: 673-81
72. Kayed R. Anti-Tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 2010;6:931-5
73. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) Tau protein. Nat Genet 2000;26:127
74. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological Tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559-66
75. Novak M. Tau vaccine: active immunization with misfolded Tau protein attenuates Tau pathology in the transgenic rat model of Tauopathy. Alzheimer Dement 2009;5:P93
76. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human Tau isoforms. J Neurosci 2005;25: 5446-54
77. Dodel R, Balakrishnan K, Keyvani K, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011;31: 5847-54
78. Bi BT, Lin HB, Cheng YF, et al. Promotion of b-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer's disease. Neurochem Int 2011;60:257-66
79. Otvos L Jr, Feiner L, Lang E, et al. Monoclonal antibody PHF-1 recognizes Tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994;39:669-73
80. Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286:34457-67
81. Castillo DL, Lasagna-Reeves C, Guerrero-Munoz MJ, et al. Modulation of Tau oligomers by passive vaccination. Soc Neurosci 2011;347:11
82. Morgan D, Lee D, Brownlow M, et al. Opposing roles of microglial activation in amyloid depositing and Tau depositing transgenic mice. Neurodegenerative Diseases 2011;8(Suppl 1
83. Winton MJ, Lee EB, Sun E, et al. Intraneuronal APP, not free Ab peptides in 3xTg-AD mice: implications for Tau versus Ab-mediated Alzheimer neurodegeneration. J Neurosci 2011;31:7691-9
84. Landry N, Ward BJ, Tre'panier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010;5: e15559
85. Available from: www.medicago.com/ English/Products/Pandemic-flu-vaccine/ default.aspx